Mode
Text Size
Log in / Sign up
Phase 4 N=15 Other

Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women

Healthy Lactating Women

Enrolled (actual)
15
Serious AEs
0.0%
Results posted
Jun 2024
Primary outcome: Primary: AUCtau,Milk — 21.4; 1.59 µg•h/mL, (CV%)

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
SPN-812 (600mg, QD) (Drug)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
Supernus Pharmaceuticals, Inc.
Primary completion
Sep 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
AUCtau,Milk
21.4; 1.59
PRIMARY
Cmax,Milk
1.41; 0.0940
PRIMARY
Tmax,Milk
5.53; 9.53
PRIMARY
Ctrough,Milk
0.426; 0.0480
PRIMARY
Cave,Milk
0.912; 0.0677
SECONDARY
Plasma AUCtau,ss
63.4; 42.3
SECONDARY
Plasma Cmax,ss,
3.92; 2.73
SECONDARY
Plasma Tmax,ss
5.00; 6.00
SECONDARY
Plasma CL/Fss,
9.46; NA
SECONDARY
Plasma Cave,ss
2.64; 1.76
SECONDARY
Plasma Ctrough,ss
1.36; 0.878
SECONDARY
Breast Milk-plasma Ratio (ML/PL)
0.338; 0.0376
SECONDARY
Estimated Daily Infant Dosage (EDID, mg/kg/Day)
0.134; 0.00994; 0.178; 0.0133
SECONDARY
Relative Infant Dose (RID, %) at Plasma Steady-state
1.53; 0.114; 2.04; 0.152
SECONDARY
Daily Infant Dosage (DID)
0.511; 0.0357
SECONDARY
Number of Participants With Adverse Events (AEs)
12

Summary

This is an open label, single treatment, multiple doses lactation study of SPN-812 in healthy lactating women. The study is designed to assess the excretion of viloxazine and its major metabolite 5-HVLX-gluc into breast milk following repeated administration of SPN-812 600 mg, QD. This study is comprised of Screening, Inpatient Admission, Treatment Period and End of Study (EOS). The total duration of the study is up to 32 days including Screening up to 28 days and 4 days of Treatment Period. Subjects will remain in the inpatient unit for 5 days, including the day of admission to the inpatient unit (Day -1), 3 days of dosing SM (Days 1-3), and the day of discharge (Day 4).

Eligibility Criteria

Inclusion Criteria

  • Healthy lactating females, 18 to 45 years of age, who are actively breastfeeding (including baby to breast, bottle feeding mother's expressed breast milk) and are at least 12 weeks postpartum of a healthy term newborn infant (no medical complications) and not more than 2 years postpartum. Lactation must be well established and the mother is exclusively breast feeding her baby (not providing supplemental formula) prior to the day of admission to inpatient unit.
  • Has a body mass index between 18 to 35 kg/m2, included.
  • Is considered medically healthy by the Investigator via assessment of physical examination (neurological examinations included), medical history, clinical laboratory tests, vital signs, Columbia-Suicide Severity Rating Scale (C-SSRS) and electrocardiogram (ECG).
  • Is willing to temporarily discontinue breastfeeding their infant and discard all their breast milk for 7 consecutive days, including day of admission to inpatient unit (Day -1), 3 consecutive days of dosing SM while in the inpatient unit (Days 1 to 3), and 3 consecutive days after last dose of SM (including day of discharge from the inpatient unit and 2 days at home; Days 4 to 6); and willing to store sufficient amount of breast milk (e.g., breast milk pumped and stored in freezer before the day of admission), and/or infant formula to feed infant during these 7 consecutive days.
  • Is either sexually inactive (abstinent) or, if sexually active, must agree to use/practice one of the following acceptable birth control methods beginning during the screening period prior to the first dose of SM, throughout the inpatient study, and for 3 days following the last dose of SM (Day 3):
  • intra-uterine contraceptive device;
  • barrier method: condom with spermicidal foam/gel/film/cream/suppository or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository;
  • is surgically sterile or male partner is surgically sterile;
  • established use of a patch, vaginal ring, oral, injected or implanted hormonal methods of contraception that can be used in lactating women;
  • Essure® procedure performed at least 6 months prior to Screening and had hysterosalpingogram after the Essure procedure to document tubal occlusion prior to screening.
  • Must not be in the process of weaning before admission and have maintained an adequate breast milk supply with regularly pumping or routine breastfeeding (e.g., pumping or feeding 3-4 times a day) at admission.
  • Is currently a non-smoker who has not used tobacco or nicotine-containing products (chewed or smoked) or replacement products, including electronic cigarettes, within 3 months prior to screening and a negative cotinine test result at Screening.
  • Agrees to use only the emollient or nipple cream recommended by the investigator for use during the sampling period, if needed.
  • Able to voluntarily provide written informed consent to participate in the study.
  • Able to understand and willing to comply with all study requirements.
  • Able and willing to swallow capsules whole, without crushing, chewing, or cutting.

Exclusion Criteria

  • Participation in any other investigational study drug trial in which receipt of an investigational study drug within 30 days or 5 half-lives before Screening, whichever is longer.
  • Is unwilling or unable to comply with the Lifestyle guidelines presented in the protocol during the study period.
  • Has history or presence of clinically significant systemic disease (including psychological and psychiatric disorders).
  • Is currently using, or tests positive at Screening for cotinine, alcohol, or drugs (opiates, methadone, cocaine, amphetamines [including ecstasy], barbiturates, PCP, benzodiazepines, and THC/cannabis).
  • Is pregnant (has positive serum pregnancy test at Screening) or becomes pregnant during study (has positive urine pregnancy test).
  • Has history of breast implants, breast augmentation, or breast reduction surg
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06259331). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search